Literature DB >> 33757872

Is there a place for surgical repair in adults with spondylolysis or grade-I spondylolisthesis-a systematic review and treatment algorithm.

Naresh Kumar1, Sirisha Madhu2, Naveen Pandita2, Miguel R D Ramos2, Barry W L Tan2, Keith G Lopez2, Sridharan Alathur Ramakrishnan2, Paul Jonathan2, Colum P Nolan3, Dinesh Shree Kumar4.   

Abstract

OBJECTIVES: Pars repair is less explored in adults due to associated disc degeneration with advancing age. The aim of our systematic review was to define optimal characteristics of adults with spondylolysis/grade-I spondylolisthesis suitable for pars repair and evaluate the feasibility, effectiveness, and safety of standard repair techniques in these adults.
METHODS: This systematic review is reported in line with PRISMA-P and protocol is registered with PROSPERO (CRD42020189208). Electronic searches were conducted in PubMed, Embase, Scopus, and Web of Science in June 2020 using systematic search strategy. Studies involving adults aged ≥18-years with spondylolysis/grade-1 isthmic spondylolisthesis treated with standard pars repair techniques were considered eligible. A two-staged (titles/abstracts and full-text) screening was conducted independently by three authors followed by quality assessment using the Joanna Briggs Institute critical appraisal checklist for selection of final articles for narrative synthesis.
RESULTS: A total of 5,813-articles were retrieved using systematic search strategy. First screening followed by removal of duplicates resulted in 111-articles. Second (full-text) screening resulted in exclusion of 64-articles. A final 47-articles were considered for data extraction after quality assessment. A total of 590-adults were enrolled across 47-studies; 93% were 'young adults' (18-35 years); 82% were males. Persistent low back pain was the common presenting complaint. Lysis defect was primarily bilateral (96.4%) and L5 was the most involved level (68.5%). Majority had no disc degeneration (83.5%) and had spondylolysis as the primary diagnosis (86%); only 14% had grade-I spondylolisthesis. Pars infiltration test was conducted in 22-studies and discography in 8-studies. Duration of prior conservative therapy was 3 to 72-months. Buck's repair was the commonest technique (27-studies, 372-adults). Successful repair was reported in 86% of patients treated with Buck's and ≥90% treated with Scott's, Morscher's and pedicle-screw-based techniques. Improvement in pain/functional outcomes, union rate and rate-of-return to sports/activity was high and comparable across all techniques. Intraoperative blood loss was low with minimally invasive versus traditional repair. The overall complication rate was 11.9%, with implant failure being the major complication.
CONCLUSIONS: Our systematic review establishes a definite place for lysis repair in carefully selected adults with spondylolysis/grade-I spondylolisthesis. We propose a treatment algorithm for optimizing patient selection and outcomes. We conclude that adults with age 18 to 45 years, no/mild disc or facet degenerative changes, positive diagnostic infiltration test, and normal preoperative discography will have successful outcomes with pars repair, regardless of the technique.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adults; Direct pars repair; Low-grade spondylolisthesis; Spondylolisthesis; Spondylolysis; Surgical repair

Mesh:

Year:  2021        PMID: 33757872     DOI: 10.1016/j.spinee.2021.03.011

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  2 in total

Review 1.  A Review of Treatment for Acute and Chronic Pars Fractures in the Lumbar Spine.

Authors:  Alexander A Linton; Wellington K Hsu
Journal:  Curr Rev Musculoskelet Med       Date:  2022-05-02

2.  Surgical Reduction and Direct Repair Using Pedicle Screw-Rod-Hook Fixation in Adult Patients with Low-Grade Isthmic Spondylolisthesis.

Authors:  Yongjian Gao; Chen Zhao; Lei Luo; Liehua Liu; Lichuan Liang; Dianming Jiang; Pei Li; Qiang Zhou
Journal:  Pain Res Manag       Date:  2022-08-10       Impact factor: 2.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.